Proteomic identification of haptoglobin as a stroke plasma biomarker in spontaneously hypertensive stroke-prone rats

Life Sciences

Volumn 83, Issue 17-18, 2008, Pages 625-631

  Kiga, Chizuru ^a,b   Sakurai, Hiroaki ^a   Goto, Hirozo ^a   Hayashi, Kazuko ^a   Shimada, Yutaka ^a   Saiki, Ikuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Toyama New Industry Organization   (Japan)

Author keywords

Biomarker; Haptoglobin; ProteinChip; SELDI TOF MS; Stroke

Indexed keywords

HAPTOGLOBIN; VERAPAMIL;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HYPERTENSION; IMMUNOBLOTTING; MALE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEOMICS; RAT; STROKE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; HAPTOGLOBINS; HYPERTENSION; MALE; PROTEOMICS; RATS; RATS, INBRED SHR; RATS, WISTAR; STROKE; VERAPAMIL; WEIGHT LOSS;

RATTUS; RATTUS NORVEGICUS;

EID: 53249153363     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.08.013     Document Type: Article

References (28)

1. Adam B.L., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., Semmes O.J., Schellhammer P.F., Yasui Y., Feng Z., and Wright Jr. G.L. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Research 62 (2002) 3609-3614
2. Asleh R., Marsh S., Shilkrut M., Binah O., Guetta J., Lejbkowicz F., Enav B., Shehadeh N., Kanter Y., Lache O., Cohen O., Levy N.S., and Levy A.P. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circulation Research 92 (2003) 1193-1200
3. Cazares L.H., Adam B.L., Ward M.D., Nasim S., Schellhammer P.F., Semmes O.J., and Wright Jr. G.L. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clinical Cancer Research 8 (2002) 2541-2552
4. Chapelle J.P., Albert A., Smeets J.P., Heusghem C., and Kulbertus H.E. Effect of the haptoglobin phenotype on the size of a myocardial infarct. The New England Journal of Medicine 307 (1982) 457-463
5. Delanghe J.R., Duprez D.A., De Buyzere M.L., Bergez B.M., Callens B.Y., Leroux-Roels G.G., and Clement D.L. Haptoglobin polymorphism and complications in established essential arterial hypertension. Journal of Hypertension 11 (1993) 861-867
6. Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. The American Journal of Cardiology 38 (1976) 786-800
7. Issaq H.J., Veenstra T.D., Conrads T.P., and Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochemical Biophysical Research Communications 292 (2002) 587-592
8. Kiga C., Nakagawa T., Koizumi K., Sakurai H., Shibagaki Y., Ogawa K., Goto H., and Saiki I. Expression patterns of plasma proteins in spontaneously diabetic nephritic rats after oral administration of a Kampo medicine, Hachimi-jio-gan, using SELDI ProteinChip platform. Biological & Pharmaceutical Bulletin 28 (2005) 1031-1037
9. Kozak K.R., Amneus M.W., Pusey S.M., Su F., Luong M.N., Luong S.A., Reddy S.T., and Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 12343-12348
10. Langlois M.R., and Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clinical Chemistry 42 (1996) 1589-1600
11. Laurell C.B., and Nyman M. Studies on the serum haptoglobin level in hemoglobinemia and its influence on renal excretion of hemoglobin. Blood 12 (1957) 493-506
12. Liggett W.S., Barker P.E., Semmes O.J., and Cazares L.H. Measurement reproducibility in the early stages of biomarker development. Disease Markers 20 (2004) 295-307
13. Marchand A., Galen R.S., and Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. The Journal of the American Medical Association 243 (1980) 1909-1911
14. Matsumoto, C., Kojima, T., Ogawa, K., Kamegai, S., Oyama, T., Shibagaki, Y., Kawasaki, T., Fujinaga, H., Takahashi, K., Hikiami, H., Goto, H., Kiga, C., Koizumi, K., Sakurai, H., Muramoto, H., Shimada, Y., Yamamoto, M., Terasawa, K., Takeda, S., Saiki, I., (in press). A proteomic approach for the diagnosis of "Oketsu" (blood stasis), a pathophysiological concept of Japanese traditional (Kampo) medicine. Evidence-based complementary and alternative medicine.
15. Ogawa K., Kojima T., Matsumoto C., Kamegai S., Oyama T., Shibagaki Y., Kawasaki T., Fujinaga H., Takahashi K., Hikiami H., Goto H., Kiga C., Koizumi K., Sakurai H., Muramoto H., Shimada Y., Yamamoto M., Terasawa K., Takeda S., and Saiki I. Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clinical Biochemistry 40 (2007) 1113-1121
16. Okazaki T., Yanagisawa Y., and Nagai T. Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity electrophoresis. Clinica Chimica Acta 258 (1997) 137-144
17. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., and Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
18. Salvatore A., Cigliano L., Bucci E.M., Corpillo D., Velasco S., Carlucci A., Pedone C., and Abrescia P. Biochemistry 46 (2007) 11158-11168
19. Shiwa M., Nishimura Y., Wakatabe R., Fukawa A., Arikuni H., Ota H., Kato Y., and Yamori T. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochemical Biophysical Research Communications 309 (2003) 18-25
20. Sironi L., Tremoli E., Miller I., Guerrini U., Calvio A.M., Eberini I., Gemeiner M., Asdente M., Paoletti R., and Gianazza E. Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 32 (2001) 753-760
21. Wadsworth J.T., Somers K.D., Stack Jr. B.C., Cazares L., Malik G., Adam B.L., Wright Jr. G.L., and Semmes O.J. Identification of patients with head and neck cancer using serum protein profiles. Archives of Otolaryngology, Head & Neck Surgery 130 (2004) 98-104
22. Wilson L.L., Tran L., Morton D.L., and Hoon D.S. Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Annals of the New York Academy of Sciences 1022 (2004) 317-322
23. Wulfkuhle J.D., McLean K.C., Paweletz C.P., Sgroi D.C., Trock B.J., Steeg P.S., and Petricoin III E.F. New approaches to proteomic analysis of breast cancer. Proteomics 1 (2001) 1205-1215
24. Yamori Y. Overview: studies on spontaneous hypertension-development from animal models toward man. Clinical and Experimental Hypertension 13 (1991) 631-644
25. Yamori Y., Horie R., Handa H., Sato M., and Fukase M. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 7 (1976) 46-53
26. Yamori Y., Igawa T., Tagami M., Kanbe T., Nara Y., Kihara M., and Horie R. Humoral trophic influence on cardiovascular structural changes in hypertension. Hypertension 6 (1984) 27-32
27. Yang Q., Goto H., Shimada Y., Kita T., Shibahara N., and Terasawa K. Effects of Choto-san on hemorheological factors and vascular function in stroke-prone spontaneously hypertensive rats. Phytomedicine 9 (2002) 93-98
28. Zhang Y.F., Wu D.L., Guan M., Liu W.W., Wu Z., Chen Y.M., Zhang W.Z., and Lu Y. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clinical Biochemistry 37 (2004) 772-779